JPRN-C000000393已完成4 期
Entecavir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B virus - GLSG, 2006, entecavir
Gunma Liver Study Group (GLSG)0 个研究点目标入组 20 人开始时间: 2012年10月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Allergy to Lamivudine complication of chronic hepatitis coadministration of cytotoxic drugs leucopenia during pregnancy severe liver dysfunction
研究者
相似试验
已完成
4 期
Tenofovir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B viruschronic hepatitis BJPRN-C000000395Gunma Liver Study Group (GLSG)20
已完成
4 期
A open-label study of entecavir for chronic hepatitis B to determine the optimum duration of administratiochronic hepatitis BJPRN-UMIN000000644Gunma Liver Study Group70
已完成
不适用
Efficacy of entecavir as an adjuvant therapy for hepatocellular carcinoma derived from HBV infection: a prospective trialHBV related CHB/LC/HCCJPRN-UMIN000005992Tokyo University Hospital40
已完成
不适用
Efficacy of entecavir for chronic hepatitis B patients after curative treatment of hepatocellular carcinoma :randomized controlled trialJPRN-UMIN000001000niversity of Tokyo Department of Gastroenterology, Faculty of Medicine44
招募中
不适用
PegIFNalpha-2a treatment added-on entecavir for HBeAg and HBV DNA negative patients treated with long-term entecavirchronic hepatitis BJPRN-UMIN000012454Toranomon Hospital100